(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
4 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 10.87%
2.50% $ 93.00
@ $93.66
Wydano: 26 bal. 2024 @ 21:20
Zwrot: -0.70%
Poprzedni sygnał: bal. 25 - 19:08
Poprzedni sygnał:
Zwrot: 3.76 %
Live Chart Being Loaded With Signals
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 710 386 |
Średni wolumen | 805 482 |
Kapitalizacja rynkowa | 5.69B |
EPS | $0 ( 2024-02-15 ) |
Następna data zysków | ( $-1.640 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.11 |
ATR14 | $4.51 (4.85%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-28 | Landsittel Michael | Buy | 5 000 | Common Stock |
2024-03-28 | Landsittel Michael | Sell | 5 000 | Common Stock |
2024-03-28 | Landsittel Michael | Sell | 5 000 | Stock Option (Right to Buy) |
2024-03-07 | Albers Jeffrey W. | Sell | 11 033 | Common Stock |
2024-03-20 | Albers Jeffrey W. | Buy | 10 000 | Common Stock |
INSIDER POWER |
---|
36.49 |
Last 100 transactions |
Buy: 596 437 | Sell: 283 237 |
Wolumen Korelacja
Blueprint Medicines Corp Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ACBA | 0.958 |
MANH | 0.953 |
PUCK | 0.951 |
VIRI | 0.949 |
GXII | 0.947 |
AEAC | 0.946 |
ESLT | 0.946 |
RAM | 0.946 |
IVCB | 0.945 |
SKYW | 0.945 |
10 Najbardziej negatywne korelacje | |
---|---|
PEAR | -0.951 |
VORB | -0.949 |
INFN | -0.934 |
MKTX | -0.931 |
BHTG | -0.928 |
FEMY | -0.927 |
IVAC | -0.926 |
EDUC | -0.926 |
TRIT | -0.925 |
OBNK | -0.924 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Blueprint Medicines Corp Korelacja - Waluta/Towar
Blueprint Medicines Corp Finanse
Annual | 2023 |
Przychody: | $249.38M |
Zysk brutto: | $224.92M (90.19 %) |
EPS: | $-8.37 |
FY | 2023 |
Przychody: | $249.38M |
Zysk brutto: | $224.92M (90.19 %) |
EPS: | $-8.37 |
FY | 2022 |
Przychody: | $204.04M |
Zysk brutto: | $186.22M (91.27 %) |
EPS: | $-9.35 |
FY | 2021 |
Przychody: | $180.08M |
Zysk brutto: | $162.15M (90.04 %) |
EPS: | $-11.81 |
Financial Reports:
No articles found.
Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej